TARS
NASDAQTarsus Pharmaceuticals Inc.
Price$59.30-16.96 (-22.24%)
2026-03-042026-06-05
News · 26 weeks71-85%
2025-12-142026-06-07
Mix4290d
- Insider17(40%)
- SEC Filings12(29%)
- Other9(21%)
- Earnings2(5%)
- Analyst1(2%)
- Offering1(2%)
Latest news
25 items- PRAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsSEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat
- PRTarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 8:00 a.m. PT / 11:00 a.m. ET.2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 8:40 a.m. PT / 11:40 a.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and
- SECSEC Form SCHEDULE 13G filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansCena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashesThis common and often overlooked condition is characterized by eyelid redness, itching and crusting, and the collaboration encourages people to prioritize their eye health IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live in and around the eyelashes. Cena's story reflects the experience of millions who live with symptoms
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRTarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday, May 12th, at 3:40 p.m. PT / 6:40 p.m. ET.H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19th, at 8:00 a.m. PT / 11:00 a.m. ET.Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26th, at 12:30 p.m. PT / 3:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- SECSEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsGenerated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027 Management to host conference call today, May 6, 2026, at 1:30 p.m.
- PRTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad
- INSIDERDirector Pyott David E I converted options into 1,383 shares (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form DEFA14A filed by Tarsus Pharmaceuticals Inc.DEFA14A - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- SECSEC Form DEF 14A filed by Tarsus Pharmaceuticals Inc.DEF 14A - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- ANALYSTOppenheimer resumed coverage on Tarsus Pharmaceuticals with a new price targetOppenheimer resumed coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $98.00 from $105.00 previously
- PRTarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs. Calliope is a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability and pharmacokinetics of orally administered TP-05 in approximately 700 healthy adults at r
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- INSIDERSEC Form 4 filed by Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- PRTP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusIRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the National Medical Products Administration (NMPA) of the People's Republic of China. The approval was obtained by Grand Pharmaceutical Group Limited ("Grand Pharma"), Tarsus' exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis in the Greater China region, which includes the People's Republic of China, Hong Kong, Macau and Taiwan. "TP-03 is once
- INSIDERSEC Form 4 filed by Whitfield Dianne C.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Wahl Bryan4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Neervannan Seshadri4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Mottiwala Aziz4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Lin Elizabeth Yeu4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Farrow Jeffrey S4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
TARS FAQ
7 questionsWhat does Tarsus Pharmaceuticals Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in...Where does TARS stock trade?
Tarsus Pharmaceuticals Inc. (TARS) is listed on NASDAQ.What sector and industry is TARS in?
Tarsus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tarsus Pharmaceuticals Inc. go public?
Tarsus Pharmaceuticals Inc. (TARS) completed its IPO in 2020.What are analysts saying about TARS?
Tarsus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform on 2026-04-24. Recent price targets range from $1900.00 to $4400.00.What companies are similar to TARS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TARS side-by-side with any of them on Quantisnow.How can I track TARS on Quantisnow?
Quantisnow aggregates Tarsus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARS to receive live email and push alerts on every new disclosure.